Indolent lymphomas may transform into intermediate or high-grade lymphoma, a diagnosis that is usually made reached by tissue biopsy, with unfavorable prognosis. A retrospective study was performed of the clinical characteristics, treatment patterns and outcomes of 73 patients with histologic transformed lymphoma originating as follicular lymphoma (FL), chronic lymphocytic leukemia/small cell leukemia (CLL/SCL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), or low grade B cell lymphoma not otherwise specified (NOS). The median time to transformation was 55 months (range 1-258) and Diffuse Large B Cell Lymphoma (DLBCL) constituted the majority of HTL diagnosis diagnoses. There was a statistically significant longer time to the development of HTL in patients with CLL and LPL compared to other indolent lymphoma types (FL, MZL and lowgrade B cell lymphoma NOS); however, overall survival (OS) at histologic transformation was similar regardless of the indolent lymphoma type preceding HTL. Treatment with Rituximab-containing regimens have increased overall survival in HTL compared with the pre-rituximab era. In the 63 treated cases of HTL, PET showed complete remission (CR) in the majority of patients (55%) with 15% achieving partial remission (PR) and 15% having progressive disease (PD). OS at two years was approximately 60%, and 41% of patients remained alive at 5 years.
Introduction
Despite the known favorable prognosis of indolent lymphomas (IL), histologic transformation (HT) to intermediate or high-grade lymphoma is a potential and significant event. Histologic transformed lymphoma (HTL) is rarely an end point in trials of indolent lymphomas and most of the transformations are to Diffuse Large B Cell Lymphoma (DLBCL). The PRIMA trial reported a 4.1% risk of HTL at six years in follicular lymphoma patients with high tumor burden [1] ; there is paucity of data on HT in other types of indolent lymphomas. Diagnosis of HTL is ideally made by tissue biopsy, cellular morphology and immunohistochemistry with or without cytogenetics [2] . Others have defined HTL using clinical criteria [3] such as rapid progression of adenopathy, laboratory abnormalities and/or new onset of constitutional symptoms. Radiographic evidence, especially positron emission tomography (PET) scan, may be used in situations where adequate tissue diagnosis is not feasible. Current information on and the management of HTL are mostly extrapolated from retrospective studies of HTL or from prospective trials of DLBCL, despite known heterogeneity of DLBCL and exclusion of HTL patients from most trials of DLBCL [4] .
Our study aims to contribute to the existing literature on the clinical characteristics, treatment pattern and outcomes of patients with HTL.
Methods and Statistical Analysis
Electronic medical records at Beaumont Hospital were retrospectively queried for patients with a diagnosis of intermediate or high-grade non-Hodgkin's lymphoma which includes DLBCL, Mantle cell lymphoma (MCL), Burkitt Lymphoma, or High-grade B cell lymphoma, type not otherwise specified (NOS) [5] from January 2007 to December 2015. This Study was approved by the William Beaumont Hospital Institutional Review Board and a waiver of individual informed consent was granted for this retrospective review. Patients having a tissue diagnosis of HTL were then identified for analysis. Baseline characteristics were reported as median (range) or mean (standard deviation) for continuous variables as appropriate, whereas categorical variables were reported as frequency (%).
The Shapiro-Wilk test was used to assess the normality of continuous variables. Baseline characteristics of the different indolent lymphoma types were compared using the Kruskal-Wallis H-test for continuous data, and Chisquare test for categorical data. Survival was estimated using the Kaplan-Meier method. Univariate analysis of overall survival (OS) was performed with the log-rank test. A multivariate Cox proportional hazard model was constructed for OS using a limited backward elimination process. Candidate predictors for multivariate analysis were chosen to have a P < 0.20 in univariate analysis. The statistical significance level (P) was set at less than 0.05 for a two-tailed test. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 22.0. Data are presented as n (%) or *median (range).
Abbreviations: HTL, histologically transformed lymphoma; LDH, lactate dehydrogenase; WBC, white blood cell count; Hb, hemoglobin; PLT, platelet count; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone; CR, complete remission; PR, partial response; PD, progressive disease. Of the two patients diagnosed with double-hit DLBCL, the original diagnosis of both was follicular lymphoma and they both had elevated proliferative index Ki67 of 80% and 90%. One of the patients had progressive disease with Extranodal involvement was present in 58 (79%) patients at the time of HTL diagnosis, with the number of extranodal sites being 1 site in 38 patients and 2 sites in 14 patients; 6 patients had 3 or more extranodal site involvement. At the time of diagnosis of HTL, the age of the patient, sex, Ki67, LDH, albumin, number of extranodal sites, response to treatment and OS were similar regardless of the type of indolent lymphoma. However, patients with Richter's transformation tended to have more leukocytosis and thrombocytopenia while those with HTL from MZL were more likely to have normal hemoglobin at diagnosis relative to others. There was a statistically significant difference in the median (range) time in months to transformation among the different indolent lymphoma histologies, with FL, MZL and low-grade lymphoma NOS progressing in a shorter time period than CLL and LPL; p=0.035 ( 
Discussion
Despite the favorable clinical course of most indolent lymphomas, histologic transformation to aggressive lymphoma remains a significant adverse event and in the pre-rituximab era was historically associated with worse outcome compared to patients with de novo aggressive lymphoma [2] . Published retrospective cohorts of HTL patients treated with chemotherapy alone without rituximab showed 5-year OS rates of 20% to 30%, and median OS ranging between 1 and 2 years [3, 6] . A more favorable prognosis has been shown for HTL since the introduction of rituximab. A study by Ban-Hoefen et al. reported 2-year OS of 68% [7] , while 5-year OS survival of transformed lymphoma ranged from 40-70% [6] [7] [8] . These results are comparable to our study findings of 60% 2-year OS and 41% 5-year OS (Figure 1 ). However, a retrospective study of transformed DLBCL without prior RCHOP chemotherapy treatment for indolent lymphoma compared to de novo DLBCL treated with RCHOP showed no statistically significant difference in CR rate, PFS or OS between the de novo and transformed groups [8] .
Follicular lymphoma is the most common subtype of indolent lymphoma and constitutes the most common indolent lymphoma to transform to aggressive lymphoma in the literature [3, 9, 10] . There are reports of HTL in other indolent lymphoma types such as CLL/SLL, MZL, and LPL [11] [12] [13] [14] [15] . Our institutional retrospective data also identified follicular lymphoma as the most common indolent lymphomas with HTL followed by CLL. Time to histologic transformation also varies among different types of indolent lymphoma; reported time to Richter's transformation in CLL ranged from 1.8 years to 4 years [16] [17] [18] , from 2.75 years to 3.3 years in follicular lymphoma [2, 19] , and 1.9 years to 2.6 years for marginal zone lymphoma [14] . Our study showed a statistically significant longer time to HTL in LPL and CLL compared to FL, MZL and low grade lymphoma NOS. Evaluating all indolent lymphomas with HTL, Villa et al reported a median time to transformation of 3.7 years in a retrospective study [20] similar to our findings of 3.4 years in the entire patient cohort.
Survival has also been reported to be different in transformed lymphoma depending on the type of indolent lymphoma [12, 21] ; contrary to this, we found no statistically significant different in OS following histologic transformation between the types of indolent lymphoma in our study. Treatment of low-grade lymphoma was thought to have affected outcome at histologic transformation. Yuen et al. showed better outcome at transformation in patients with indolent lymphoma managed with observation [22] in a retrospective study. Another report by
Montoto et al. found a higher risk of transformation of indolent lymphoma with expectant management [23, 24] while the GELA trial did not find differing transformation risk between indolent lymphoma managed with expectant management or early treatment [25] . Our study did not find a statistically significant difference between OS after diagnosis of HTL and choice of indolent lymphoma treatment, i.e., observation or systemic therapy. Prior treatment of indolent lymphoma with rituximab or any anti CD-20 monoclonal antibody has not been reported to have any statistically significant relationship with patients' outcomes after histologic transformation [26] , also consistent with our study findings. 
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Double hit DLBCL is historically known to be resistant to chemoimmunotherapy and has a higher incidence of CNS disease. Aside from its occurrence in de novo DLBCL, it has also been reported in HTL, particularly when t (14;18) in follicular lymphoma acquires c-myc translocation [27] , as also identified in our study. Jonathan W. Friedberg proposed considering dose-adjusted R-EPOCH similar to what is prescribed for de novo double-hit lymphoma, for those patients with double-hit lymphoma in the setting of transformed follicular lymphoma without prior anthracycline exposure or salvage chemotherapy followed by ASCT in those with prior anthracycline treatment [28] .
Treatment and survival of patients with HTL continues to evolve particularly in the era of targeted therapies. Data on timing and role of HDT-ASCT in HTL continues to be debated in the rituximab era, with some studies suggesting better outcome with HDT-ASCT in CR-1 [29] [30] [31] and others finding no significant impact on survival [26] . Silvia Montoto proposed that consolidation with HDT-ASCR may be considered in patients with transformed lymphoma who received lines of chemotherapy for indolent lymphoma and treatment with R-CHOP at transformation, or for those who received RCHOP prior to HTL, required salvage chemotherapy at the time of transformation, and had good response and performance status [7] . Only one of our study patients received ASCT in CR-1.
There are a number of on-going clinical trials of DLBCL enrolling patients with HTL that are evaluating the role of (Table 4) . Many of these studies are in early stages and thus optimal treatments for DLBCL HTL will likely remain unresolved for the foreseeable future.
Conclusion
Despite improved outcome in the rituximab era, the outcome of HTL particularly in the relapsed-refractory setting remains unsatisfactory. Our retrospective study identified achievement of CR and LDH level within the normal range to statistically predict better OS. We found a statistically significant longer time to the development of HTL in patients with CLL and LPL compared to other indolent lymphoma types (FL, MZL and low-grade B cell lymphoma NOS; however, OS at histologic transformation was similar regardless of the indolent lymphoma type preceding HTL. Future directions will depend on the outcome of on-going clinical trials, the results of which will suggest novel therapeutics and provide for more evidence-based management of HTL
